How does 7V3's PB Ratio compare to its peers?

7V3 is good value based on its Price-To-Book Ratio (6.8x) compared to the peer average (12.3x).

How does 7V3's PB Ratio compare vs other companies in the DE Biotechs Industry?

7V3 is expensive based on its Price-To-Book Ratio (6.8x) compared to the European Biotechs industry average (2.4x).

What is 7V3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 7V3's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 7V3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 7V3's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Cantargia (DB:7V3) - Stock Price, News & Analysis

7V3 Stock Overview

A biotechnology company, develops antibody-based treatments for life threatening diseases. More details

7V3 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 50.11% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue (SEK0)

Earnings are forecast to decline by an average of 3.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Cantargia AB (publ) Competitors

Medigene

XTRA:MDG1

€22.6m

4SC

DB:VSC

€48.2m

2invest

XTRA:2INV

€63.8m

Heidelberg Pharma

XTRA:HPHA

€103.9m

Price History & Performance

Summary of all time highs, changes and price drops for Cantargia
Historical stock prices
Current Share Price	SEK 0.13
52 Week High	SEK 0.46
52 Week Low	SEK 0.13
Beta	1.74
11 Month Change	-54.35%
3 Month Change	-59.43%
1 Year Change	-55.90%
33 Year Change	-92.24%
5 Year Change	-91.20%
Change since IPO	-91.73%

Recent updates

Shareholder Returns

	7V3	DE Biotechs	DE Market
7D	-9.0%	-0.7%	-0.02%
1Y	-55.9%	-17.2%	8.2%

Return vs Industry: 7V3 underperformed the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 7V3 underperformed the German Market which returned 8.2% over the past year.

Price Volatility

Is 7V3's price volatile compared to industry and market?
7V3 volatility
7V3 Average Weekly Movement	21.7%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: 7V3's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7V3's weekly volatility has increased from 17% to 22% over the past year.

About the Company

Founded	Employees	CEO	Website
2009	21	Goran Forsberg	cantargia.com

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.

Cantargia AB (publ) Fundamentals Summary

How do Cantargia's earnings and revenue compare to its market cap?
7V3 fundamental statistics
Market cap	€28.94m
Earnings (TTM)	-€16.83m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Is 7V3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7V3 income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 193.53m
Earnings	-SEK 193.53m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 21, 2025

Earnings per share (EPS)	-1.05
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 7V3 perform over the long term?

See historical performance and comparison

7V3 Stock Overview

Rewards

Risk Analysis

Cantargia AB (publ) Competitors

XTRA:MDG1

€22.6m

DB:VSC

€48.2m

XTRA:2INV

€63.8m

XTRA:HPHA

€103.9m

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Recent updates

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes